Austrian company, Biocrates Life Sciences, has acquired a specialist in metabolomics biomarker development and healthcare services, Metanomics Health, to serve the metabolomics market as a total solution provider, with a focus on healthcare and pharmaceutical applications.
Acquisition
“Together, Biocrates and Metanomics Health provide the broadest technology and metabolomics product portfolio in the industry. These will enable us to provide deep metabolic phenotyping through targeted metabolomics profiling services, customised assays, targeted screening kits, and comprehensive data interpretation. Moreover, the merger will enable us to develop kits for both diagnostics and companion diagnostics”, said Biocrates’ CEO Dr Wulf Fischer-Knuppertz. “We are looking forward to further developing and expanding our offerings in the life science market. The completed financing round along with the merger allows us to increase our growth through accelerated kit development and regional sales expansion.”
Dr Tim Bölke, Metanomics Health’s managing director, who will continue to lead operations in Berlin and join the management team of Biocrates as chief medical officer commented: “Metabolomics has the potential to bring a new dimension to diagnosis and patient stratification in precision medicine as well as to improve the drug discovery and development process. We are looking forward to extending and broadening our services and offerings to improve prognosis and diagnosis in areas of high unmet medical need, ultimately leading to earlier and better treatments.”
Additionally, Biocrates has closed a significant funding round to support future growth with a minority share of the company being retained by BASF Plant Science (a participant in the financing round).